Kestra Medical Technologies reports developments as a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular disease. Its updates center on the Cardiac Recovery System platform and the ASSURE WCD, a wearable cardioverter defibrillator used for patients at elevated risk of sudden cardiac arrest.
Recurring news includes fiscal results and revenue guidance, clinical data from the ASSURE WCD post-approval study, product and algorithm updates, healthcare conference presentations, and collaborations aimed at expanding diagnostic insight during cardiac recovery.
Kestra Medical Technologies (Nasdaq: KMTS) earned a five-star rating on Newsweek’s list of America’s Greatest Mid-Market Companies 2026.
Only 30 of the 100 honorees earned five stars. Kestra was the only company in the Medical Equipment Manufacturing category to receive that rating. Newsweek and Plant-A Insights Group assessed financial performance, workforce experience, innovation and sustainability for the inaugural ranking.
CAIRDAC announced Raymond W. Cohen’s appointment as chairman of its board of directors on September 24, 2026. The pre-revenue company is developing the Autonomous Leadless Pacing System (ALPS), a pacemaker designed to draw power from the movement of the heart.
Cohen co-founded and led Axonics (AXNX), which went public in 2018 and was acquired by Boston Scientific for $3.7 billion in late 2024. In 2025, as chairman of SoniVie, he led its $600 million sale and later led the $533 million sale of Nalu Medical. He also serves on the board of Kestra Medical Technologies (KMTS).
Kestra Medical Technologies (KMTS) reported fiscal first quarter 2027 revenue of $31.0 million, up 60% year over year for the period ended July 31, 2026.
Gross profit rose to $17.5 million and gross margin expanded to 56.5% from 45.7%, driven by higher volumes, a larger share of in-network patients and cost improvement programs. Revenue growth was supported by wearable cardioverter defibrillator market expansion, competitive share gains, new sales territories and improved revenue cycle management.
GAAP operating expenses increased to $55.2 million from $37.7 million, and GAAP net loss widened to $44.1 million from $25.8 million. Adjusted operating expenses were $44.2 million and adjusted EBITDA loss was $24.0 million.
Kestra ended the quarter with $244.7 million in cash, cash equivalents and investments and total liquidity of about $320 million. FY27 revenue guidance was raised to $141 million, up from $137 million and 48% above FY26.
Kestra Medical Technologies (KMTS) has appointed Daniel Finney as Vice President of Research & Development and member of its executive leadership team, succeeding Phillip D. Foshee, Jr. following his retirement.
Finney previously served as Senior Director of New Product Development at Kestra and played a hands-on role in developing the ASSURE WCD within the Cardiac Recovery System platform. He will lead initiatives across internal R&D, strategic partnerships, and applications of AI, with priorities guided by clinical evidence and real-world insights, including data from the ASSURE Clinical Evaluation Post-Approval Study (ACE-PAS), described as the largest prospective real-world study of wearable cardioverter defibrillators to date.
Kestra Medical Technologies (Nasdaq: KMTS) will report its first quarter fiscal 2027 financial results after the market close on Monday, September 14. Management will host a conference call at 4:30 p.m. Eastern Time, with a live and archived webcast available in the Investor Relations “Events” section.
Kestra (Nasdaq: KMTS) appointed Curtis Kopf as Senior Vice President of Customer Experience, a newly created role overseeing the patient journey for the ASSURE WCD from order approval through therapy completion and device return. He will align people, processes, and technology to support providers and patients.
Kopf previously led global customer experience at Insulet and held senior experience and digital roles at REI. According to Kestra, his appointment coincides with investments in commercial capabilities and artificial intelligence initiatives aimed at driving operating leverage in customer-facing operations and supporting the company’s next stage of growth.
Kestra Medical Technologies (Nasdaq: KMTS) entered a five-year term loan facility with funds managed by Pharmakon Advisors, providing up to $200 million in non-dilutive financing. The structure includes a $75 million tranche funded at closing (used in part to retire a $45 million term loan and pay fees), a $25 million tranche available at Kestra’s option through July 2027, and a $50 million tranche available through June 2028, subject to achieving $150 million in trailing 12-month revenue. An additional $50 million uncommitted tranche for acquisitions is available subject to Pharmakon’s consent.
The facility features 48 months of interest-only payments, extendable by 12 months upon a revenue milestone, with interest at 3‑month SOFR + 5.5%, subject to a 3.25% SOFR floor. According to Kestra, cash, cash equivalents and investments were $262 million as of April 30, 2026, and total liquidity including unused committed availability is about $357 million. Armentum Partners acted as financial advisor.
Kestra Medical Technologies (Nasdaq: KMTS) reported fiscal 4Q26 revenue of $28.6 million, up 66% year over year, and FY26 revenue of $95.1 million, up 59% versus FY25. Fourth-quarter gross margin improved to 54.8% from 44.3%, while FY26 gross margin rose to 51.4% from 40.5%. FY27 revenue is guided to $137 million, implying 44% growth.
According to Kestra, 4Q26 ASSURE® system prescriptions increased 63% to 6,357, and FY26 prescriptions rose 57% to 20,720. 4Q26 GAAP net loss narrowed to $38.8 million, but FY26 GAAP net loss widened to $131.6 million. Adjusted EBITDA loss was $26.7 million in 4Q26 and $87.0 million for FY26. Cash, cash equivalents and investments totaled $262.2 million, with net cash used in operating activities reduced to $18.7 million for the year.
Kestra Medical Technologies (Nasdaq: KMTS) will report fourth quarter fiscal 2026 financial results after the market closes on Tuesday, July 14.
Management will host a conference call at 4:30 p.m. Eastern Time, with a live and archived webcast available in the investor relations website’s Events section.
Kestra Medical Technologies (Nasdaq: KMTS) will present at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, 2026 at 2:20 p.m. PT.
Investors and interested parties can watch a live webcast and access a replay via the Kestra investor relations website.